Advances in the Treatment of Relapsed/Refractory Immune Thrombocytopenia With Keith McCrae, MD, and Phyllis McKiernan, APN, MSN, OCN®

Immune thrombocytopenia is an acquired immune-mediated disorder defined as a peripheral blood platelet count <100 x109/L with no known cause (Rodeghiero et al, 2009). The incidence is estimated to be 1.6 to 3.9 per 100,000 patient-years in adults and 0.46 to 12.5 per 100,000 patient-years in children (Terrell et al, 2010). Research has shown that the burden of ITP is significant. A survey of more than 1,300 patients across 13 countries showed 36% reported a high impact on emotional well-being...

New Perspectives on Diagnosis and Treatment of EGFR Exon 20 Insertion–Mutant NSCLC With Helena Yu, MD, and Maria Arcila, MD

An estimated 235,760 new cases of lung cancer are reported in the United States annually, and 131,880 people die of the disease. Approximately 84% of cases are classified as non-small cell lung cancer (NSCLC) (ACS, 2021). The most frequent genomic aberration among patients with NSCLC is the epidermal growth factor receptor (EGFR) mutation, approximately 2%-10% of which are exon 20 insertion mutations (Kumari et al, 2019; Dersarkissian et al, 2019). Exon 20 insertion mutations are a heterogenous ...

Adjuvant Nivolumab Approved for Resected Esophageal and GEJ Cancer

The FDA has granted approval to nivolumab (Opdivo®, Bristol Myers Squibb) for patients with completely resected esophageal or gastroesophageal junction (GEJ) cancer who have residual pathologic disease after prior neoadjuvant chemoradiotherapy. "No adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemoradiotherapy and surgery for esophageal or gastroesophageal junction cancer," wrote the investigators of the phase 3 CheckMate 577 trial...

Sacituzumab Govitecan for Advanced Urothelial Cancer: Petros Grivas, MD, PhD

Recently, the FDA granted accelerated approval to sacituzumab govitecan (Trodelvy®, Immunomedics), an antibody-drug conjugate, for patients with locally advanced or metastatic urothelial cancer whose disease progressed following treatment with platinum-containing chemotherapy and a programmed cell death protein 1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitor. In this interview with Oncology Data Advisor, Dr. Petros Grivas, Associate Professor and Clinical Director of the Genitourinary Cance...

FDA Approves Sacituzumab Govitecan for Advanced Urothelial Cancer

Sacituzumab govitecan (Trodelvy®, Immunomedics) has been granted accelerated approval for patients with locally advanced or metastatic urothelial cancer following treatment with platinum–containing chemotherapy and a programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitor. "Patients with metastatic urothelial cancer have limited options after progression on platinum and checkpoint inhibitors," wrote the investigators of the phase 2 TROPHY-U-01 study (NCT03547973), on w...

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.